Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2016-12-23 M&A Activity
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Umowa - Content (PL)
M&A Activity Classification · 95% confidence The document text describes a specific business transaction: Celon Pharma S.A. signing a license agreement for distribution rights of a product (an inhaler) in France with a global pharmaceutical company. This agreement involves granting exclusive rights and receiving compensation (1.5 million EUR for the Issuer). This type of corporate action, related to business development, licensing, or strategic partnerships, does not fit neatly into standard periodic reports (10-K, IR, ER) or governance documents. It is a material event announcement. Given the options, 'Capital/Financing Update' (CAP) is for fundraising/capital structure, 'M&A Activity' (TAR) is for takeovers/mergers, and 'Regulatory Filings' (RNS) is the general fallback. Since this is a significant business development/licensing deal announcement, and there isn't a specific 'Business Development' code, the most appropriate classification among the provided specific codes is difficult. However, it is a report of a significant corporate event that impacts future revenue/operations. If this were a US filing, it might be an 8-K item 1.01 (Entry into a Material Definitive Agreement). In the context of the provided definitions, it is a material corporate event announcement. Since it is not about financing (CAP), M&A (TAR), or insider trading (DIRS), and it is not a standard financial report, it falls best under the general 'Regulatory Filings' (RNS) as a miscellaneous material announcement, or potentially 'Legal Proceedings Report' (LTR) if interpreted broadly as a contractual agreement, but RNS is the safer fallback for non-standard material news.
2016-12-23 Polish
Podpisanie umowy w zakresie licencji i dystrybucji leku na terenie Francji - Content (PL)
Regulatory Filings Classification · 94% confidence The document text describes a specific business transaction: the signing of a license agreement for distribution rights of a pharmaceutical product (fluticasone and salmeterol combination in a dry powder inhaler) between the Issuer (Celon Pharma S.A.) and a global pharmaceutical company for the French territory. This type of agreement, involving licensing, distribution rights, and associated financial compensation (1.5 million EUR), is a significant corporate event related to business operations and potential future revenue streams. It does not fit the definitions for standard financial reports (10-K, IR, ER), management changes (MANG), or shareholder votes (AGM-R, DVA). It is most closely related to corporate transactions or material business updates. Given the options, 'M&A Activity' (TAR) is often used broadly for significant commercial agreements that alter market scope, but 'Regulatory Filings' (RNS) serves as the best general category for material, non-standard corporate announcements that don't fit the highly specific financial or governance codes. Since this is a specific commercial agreement announcement, and not a standard financial filing, RNS is the most appropriate fallback for a material, non-standard disclosure.
2016-12-23 Polish
Wybór podmiotu uprawnionego do badania sprawozdań finansowych - Content (PL)
Audit Report / Information Classification · 99% confidence The document text, written in Polish, announces that the Supervisory Board of Celon Pharma S.A. selected PricewaterhouseCoopers (PWC) to audit the company's financial statement for the fiscal year 2016. This is a formal notification regarding the appointment of an external auditor for the annual financial statements. This aligns directly with the definition of an Audit Report / Information (AR), which covers applied accounting principles and audit selection, although it is not the audit report itself, it is the announcement related to the audit process. It is not an Annual Report (10-K) as it only concerns the auditor appointment, not the full financial results. It is not an Earnings Release (ER) or Interim Report (IR). It is most closely related to the audit process, fitting the 'AR' category better than the general 'RNS' fallback, as 'AR' specifically mentions 'applied accounting principles' and regulatory stress tests, implying audit-related activities. FY 2016
2016-12-16 Polish
Notyfikacja
Director's Dealing Classification · 99% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). It details a transaction involving shares of Celon Pharma S.A. by a person closely associated with a member of the Supervisory Board (Osoba blisko związana z Panem Arturem Wieczorkiem, Członkiem Rady Nadzorczej). Specifically, it reports a 'Kupno' (Buy) transaction of 813 shares at 24.50 PLN on 15.12.2016. This content directly corresponds to the reporting of personal share transactions by company directors and executives (insider trades), which maps precisely to the Director's Dealing category.
2016-12-16 Polish
Notyfikacja
Director's Dealing Classification · 99% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). It details a transaction (Kupno/Buy) involving shares of Celon Pharma S.A. by a member of the Supervisory Board (Artur Wieczorek). Article 19 of MAR (Market Abuse Regulation) mandates disclosures for transactions conducted by persons discharging managerial responsibilities (PDMRs). This directly corresponds to the definition of Director's Dealing (insider trades by directors/executives).
2016-12-16 Polish
Powiadomienia o transakcjach dotyczących akcji Celon Pharma S.A. - Content (PL)
Director's Dealing Classification · 99% confidence The document text is very short (278 characters) and states that the Management Board received notifications regarding transactions in the company's shares from a person holding a management position and a closely related person on December 16, 2016. It explicitly mentions that the content of the notifications is attached ('Treść powiadomień Spółka przesyła w załączeniu'). This structure—a brief announcement stating that detailed transaction reports are attached—strongly suggests a notification of insider trading activity. The category 'Director's Dealing' (DIRS) covers reports of personal share transactions by directors and executives. Given the brevity and the reference to attached notifications, this is the announcement of the dealing, which fits DIRS better than the general fallback RNS, as the subject matter is highly specific.
2016-12-16 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.